Small Molecule · HS-10380

Obuprazine (HS-10380)

Obuprazine (HS-10380) is an oral, once-daily investigational antipsychotic discovered and developed by Hansoh Pharma (China). Hansoh describes it as a multi-target agent that is a partial agonist at dopamine D2/D3 and serotonin 5-HT1A receptors with potent 5-HT2A antagonism, intended to improve positive, negative and cognitive symptoms of schizophrenia. In a 363-patient Chinese Phase 2b trial in acute schizophrenia (NCT07550387), all three dose ranges (1.5-3 mg, 4.5-6 mg, 6-9 mg) beat placebo on the PANSS total score at Day 42, with aripiprazole as active control; Hansoh reported the safety profile as generally favorable and said the results support moving into Phase 3.

Also known as: HS-10380, HS 10380, HS10380, obuprazine, 2640663-79-0, N-(trans-3-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclobutyl)-1,3-oxazole-2-carboxamide

Key facts

Modality
Small molecule
Chemical class
arylpiperazine, cyclobutane, oxazole
Chemistry
Achiral
Mechanism
D2 Partial agonist
Highest phase
Phase 2
Lead indication
Schizophrenia
Trials
4 tracked · 2 sites

Mechanism of action#

Per Hansoh, obuprazine is a partial agonist at dopamine D2 and D3 receptors and at serotonin 5-HT1A receptors, with potent antagonism at 5-HT2A receptors, a multi-target profile intended to improve positive, negative and cognitive symptoms while reducing adverse effects. No binding affinities or functional potencies have been published.

TargetActionAffinity
D2primaryDRD2Partial agonist—ⓘ
5-HT1AHTR1APartial agonist—ⓘ
5-HT2AHTR2AAntagonist—ⓘ
D3DRD3Partial agonist—ⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
Obuprazine (HS-10380) oral tablet, once daily
Phase 2b (NCT07550387): fixed-flexible once-daily oral 1.5-3 mg, 4.5-6 mg or 6-9 mg each morning for 42 days, then a 1-week taper. Phase 1b/2 (NCT05964790): tablet orally once daily for 28 days. Phase 3 long-term safety study (NCT07759869): 1.5-6 mg.
OralOnce daily—

Development timeline#

2023202420252026TodayPhase 210 Oct 2026 — readout (met) — Phase 2b of obuprazine (HS-10380) in acute schizophrenia met its primary endpoint: all three dose ranges beat placebo on PANSS total change at Day 42 (LSMD -16.7, -13.2, -14.7; aripiprazole -12.1); presented at ECNP 2026.10 Oct 2026 — Conference presentation — Obuprazine (HS-10380) Phase 2b data presented at ECNP 202612 Aug 2026 — Trial registered — Phase 3 long-term safety study of HS-10380 in schizophrenia registered19 Jan 2026 — Trial (portion) completed — Phase 2b of HS-10380 in acute schizophrenia completes23 Jul 2024 — IND/CTA clearance — China CDE approves clinical trials of HS-10380 in manic episodes of bipolar I disorder23 May 2024 — phase change — Phase 2b in hospitalized adults with acute schizophrenia (NCT07550387, HS-10380-202) started (actual date per ClinicalTrials.gov); primary completion 2026-01-02, study completion 2026-01-19. Registered retrospectively (first posted 2026-04-24).23 May 2024 — Trial started — Phase 2b of HS-10380 in acute schizophrenia starts1 Mar 2022 — IND/CTA clearance — China CDE clears first clinical trial of HS-10380 in schizophreniaPhase 11 Aug 2022 — phase change — First-in-human SAD/MAD study in Chinese healthy adults (NCT05480592, HS-10380-101) started per ClinicalTrials.gov (registered under schizophrenia; record status since UNKNOWN).Phase 1/230 Jul 2023 — phase change — Phase 1b/2 in Chinese adults with schizophrenia (NCT05964790, HS-10380-201) registered with an ESTIMATED start of 2023-07-30; the record was never updated (status UNKNOWN), so the date is approximate.
Phase change Readout Event UpcomingHover a marker for details.
Phase 2Mar 2022 – Oct 2026
  1. metPhase 2b of obuprazine (HS-10380) in acute schizophrenia met its primary endpoint: all three dose ranges beat placebo on PANSS total change at Day 42 (LSMD -16.7, -13.2, -14.7; aripiprazole -12.1); presented at ECNP 2026.↗
  2. Conference presentationObuprazine (HS-10380) Phase 2b data presented at ECNP 2026↗
  3. Trial registeredPhase 3 long-term safety study of HS-10380 in schizophrenia registered
  4. Trial (portion) completedPhase 2b of HS-10380 in acute schizophrenia completes
  5. IND/CTA clearanceChina CDE approves clinical trials of HS-10380 in manic episodes of bipolar I disorder↗
  6. Phase 2b in hospitalized adults with acute schizophrenia (NCT07550387, HS-10380-202) started (actual date per ClinicalTrials.gov); primary completion 2026-01-02, study completion 2026-01-19. Registered retrospectively (first posted 2026-04-24).
  7. Trial startedPhase 2b of HS-10380 in acute schizophrenia starts
  8. IND/CTA clearanceChina CDE clears first clinical trial of HS-10380 in schizophrenia↗
Phase 1/2Jul 2023
  1. Phase 1b/2 in Chinese adults with schizophrenia (NCT05964790, HS-10380-201) registered with an ESTIMATED start of 2023-07-30; the record was never updated (status UNKNOWN), so the date is approximate.
Phase 1Aug 2022
  1. First-in-human SAD/MAD study in Chinese healthy adults (NCT05480592, HS-10380-101) started per ClinicalTrials.gov (registered under schizophrenia; record status since UNKNOWN).

Obuprazine (HS-10380) for Schizophrenia#

Phase 2ActiveSchizophrenia indication →

Obuprazine (HS-10380), an oral D2/D3 and 5-HT1A partial agonist with potent 5-HT2A antagonism from Hansoh Pharma, for schizophrenia in China. The Phase 2b trial (NCT07550387, HS-10380-202) randomized 363 Chinese adults hospitalized with acute schizophrenia to three once-daily dose ranges (1.5-3 mg, 4.5-6 mg, 6-9 mg), aripiprazole or placebo for 42 days. All three doses met the primary endpoint, with least-squares mean differences in PANSS total score change versus placebo of -16.7, -13.2 and -14.7 (aripiprazole -12.1), plus improvements in positive, negative and cognitive domains. Hansoh said safety was generally favorable with mostly mild-to-moderate adverse events, and that the results support moving into Phase 3. The data were presented at ECNP 2026 in Munich on 2026-10-10.

Readouts

  • 2026-10-10ReportedFull resultsmetNCT07550387

    Phase 2b of obuprazine (HS-10380) in acute schizophrenia met its primary endpoint: all three dose ranges beat placebo on PANSS total change at Day 42 (LSMD -16.7, -13.2, -14.7; aripiprazole -12.1); presented at ECNP 2026. ↗

Clinical trials#

NCT07759869HS-10380-303Phase 3Activen=500

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety of HS-10380 in Chinese Adult Patients With Schizophrenia

Started Sept 2026· Primary completion Jul 2028

NCT07550387HS-10380-202Phase 2Completedn=363

A Randomized, Double-Blind, Active-Controlled and Placebo-Controlled Phase 2b Clinical Study to Evaluate the Efficacy and Safety of HS-10380 in Chinese Adult Patients With Acute Schizophrenia

Started May 2024· Primary completion Jan 2026· 1 site across 1 country

China

NCT05964790HS-10380-201Phase 1/2Unknownn=112

A Phase Ib/II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10380 in Chinese Adults With Schizophrenia

Started Jul 2023· Primary completion Jun 2024

NCT05480592HS-10380-101Phase 1Unknownn=76

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HS-10380 in Chinese Healthy Adult Subjects

Started Aug 2022· Primary completion Jun 2023· 1 site across 1 country

China

Conference coverage#

HS-10380 appears in 1 CNS Pulse conference abstract:

Sources#

  1. ECNP 2026 | Hansoh Pharma announces Phase 2b data of obuprazine (HS-10380) in schizophrenia (2026-10-12) — Hansoh Pharmaceutical Group
  2. Hansoh Pharma's Class 1 innovative drug approved for clinical trials, intended to treat manic episodes of bipolar I disorder (2024-07-24) — Longbridge / Zhitong Finance
  3. HS-10380 in patients with schizophrenia: a phase 2b randomised placebo- and active-controlled trial (ECNP 2026, PS01-1227) — CNS Pulse (ECNP 2026 abstract)
  4. NCT05480592 (HS-10380-101) — Phase 1 SAD/MAD in Chinese healthy adults — ClinicalTrials.gov
  5. NCT05964790 (HS-10380-201) — Phase 1b/2 in Chinese adults with schizophrenia — ClinicalTrials.gov
  6. NCT07550387 (HS-10380-202) — Phase 2b in acute schizophrenia — ClinicalTrials.gov
  7. NCT07759869 (HS-10380-303) — Phase 3 long-term safety in schizophrenia — ClinicalTrials.gov